|
|
|||||||||||
Haukeland University Hospital, Bergen
National Hospital, Oslo, Norway
Ulleråker University Hospital, Uppsala, Sweden
Ullevål University Hospital, Norway
Huddinge University Hospital, Sweden
Elverum Medical Center, Elverum
Innherred Hospital, Levanger, Norway
Correspondence: Tone Tangen Haug, Haukeland University Hospital, 0021 Bergen, Norway
Declaration of interest Funding was provided by Pfizer, Inc.
Background Maintenance of treatment effect is important for the choice of treatment for social phobia.
Aims To examine the effect of exposure therapy and sertraline 28 weeks after cessation of medical treatment.
Method In this study 375 patients with social phobia were randomised to treatment with sertraline or placebo for 24 weeks, with or without the addition of exposure therapy. Fifty-two weeks after inclusion, 328 patients were evaluated by the same psychometric tests as at baseline and the end of treatment (24 weeks).
Results The exposure therapy group and the placebo group had a further improvement in scores on social phobia during follow-up: mean change in the Clinical Global Impression Social Phobia overall severity score was 0.45 (95% CI 0.16-0.65, P < 0.01) for the exposure group, and 0.25 (95% CI 0.00-0.48, P < 0.05) for the placebo group. At week 52 the sertraline plus exposure group and the sertraline-alone group had a significant deterioration on the 36-item Short Form Health Survey compared with exposure alone.
Conclusions Exposure therapy alone yielded a further improvement during follow-up, whereas exposure therapy combined with sertraline and sertraline alone showed a tendency towards deterioration after the completion of treatment.
Related articles in BJP:
This article has been cited by other articles:
![]() |
C. Gale and O. Davidson Tired and anxious BMJ, October 1, 2008; 337(oct01_2): a1241 - a1241. [Full Text] |
||||
![]() |
M. W. Otto, J. A. J. Smits, and H. E. Reese Combined Psychotherapy and Pharmacotherapy for Mood and Anxiety Disorders in Adults: Review and Analysis Focus, April 1, 2006; 4(2): 204. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. S. Baldwin, I. M. Anderson, D. J. Nutt, B. Bandelow, A. Bond, J. R. T. Davidson, J. A. den Boer, N. A. Fineberg, M. Knapp, J. Scott, et al. Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology J Psychopharmacol, November 1, 2005; 19(6): 567 - 596. [Abstract] [PDF] |
||||
![]() |
B. Bandelow and T. T. Haug Sertraline and exposure therapy in social phobia * Author's reply The British Journal of Psychiatry, March 1, 2004; 184(3): 271 - 272. [Full Text] [PDF] |
||||
![]() |
J. R Walker The benefits of exposure therapy alone may last longer than sertraline alone or sertraline plus exposure therapy in social phobia Evid. Based Ment. Health, August 1, 2003; 6(3): 90 - 90. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Psychiatric Bulletin | Advances in Psychiatric Treatment | All RCPsych Journals |